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Post-translational modifications (PTMs) regulate multiple biological functions of the
promyelocytic leukemia (PML) protein and also the fission, disassembly, and rebuilding of
PML nuclear bodies (PML-NBs) during the cell cycle. Pathway-specific PML modification
patterns ensure proper signal output from PML-NBs that suit the specific functional
requirements. Here we comprehensively review the signaling pathways and enzymes
that modify PML and also the oncogenic PML-RARα fusion protein. Many PTMs
occur in a hierarchical and timely organized fashion. Phosphorylation or acetylation
constitutes typical starting points for many PML modifying events, while degradative
ubiquitination is an irreversible end point of the modification cascade. As this hierarchical
organization of PTMs frequently turns phosphorylation events as primordial events,
kinases or phosphatases regulating PML phosphorylation may be interesting drug targets
to manipulate the downstream modifications and thus the stability and function of PML
or PML-RARα.
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INTRODUCTION
The PML protein has attracted the attention of many researchers
as it is involved in a variety of diseases and it is able to form
subnuclear structures. These are referred to as PML nuclear bod-
ies (PML-NBs) but are also known as PML oncogenic domains,
nuclear dot 10 or Kremer bodies (Bernardi and Pandolfi, 2007).
Interphase cells typically contain between 10 and 20 PML-NBs
in the nucleus, but their number and distribution varies con-
siderably depending on cell type, cell cycle phase, and stress
conditions. The human PML gene is located on chromosome
15q22 and alternative splicing of the C-terminal exons leads to
the generation of 6 nuclear isoforms and a further isoform called
PML-VII that is purely cytoplasmic (Jensen et al., 2001; Bernardi
and Pandolfi, 2007). All these PML isoforms share the first
three exons, which encode the RBCC/TRIMmotif. This tripartite
structure contains a RING (really interesting new gene) zinc-
finger, two additional zinc-finger motifs (B-box1 and B-box2)
and a DUF 3583 domain containing a coiled-coil region (Borden
et al., 1995; Jensen et al., 2001). The TRIM motif -together with
unique C-terminal domains of PML-II and PML-V allows self-
assembly. PML proteins function as scaffold proteins by assembly
to spherical PML-NBs containing the structure-forming PML
and Sp100 proteins that are organized into patches within a
50–100-nm-thick shell (Lang et al., 2010; Geng et al., 2012). High-
resolution 4Pi fluorescence laser-scanning microscopy studies
complemented with correlative electron microscopy allowed a
more detailed view on the substructure of PML-NBs which have
an outer shell, while the inner part is accessible for diffusing
nuclear factors (Lang et al., 2010). The inner part of PML-NBs
builds a bioincubator containing densely packed proteins with
exceedingly high concentrations.Molecular crowding within such
PML-NB cages slows down diffusion, facilitates stochastic inter-
actions, and makes them more efficient (Cho and Kim, 2012).
High protein concentrations can thus increase the rates of inter-
molecular interactions by several orders of magnitude (Minton,
2001). In that sense PML-NBs function as bioincubators that
allow or speed up PTMs of their permanent or transiently con-
tained resident proteins. In addition to their scaffolding function,
PML proteins may also harbor catalytic activities. PML functions
as a SUMO (small ubiquitin-like modifier) E3 ligase for inter-
action partners such as p53 and Mdm2, as revealed by in vivo
and in vitro experiments (Chu and Yang, 2011). The TRIM fam-
ily member PML may also function as an ubiquitin E3 ligase, as
suggested by the recently identified ubiquitin E3 ligase activity
for the related TRIM16 protein. Although TRIM16 lacks a classi-
cal RING domain, autoubiquitination occurs through its B-boxes
that can complex zinc atoms (Bell et al., 2012). It will now be
relevant to see whether also PML has the ability to augment ubiq-
uitination via its B-boxes. While most of the PML proteins reside
in the nucleus, a fraction of PML is also found in the cytoplasm
(Condemine et al., 2006; Jul-Larsen et al., 2010). In addition, the
splicing variant PML-VII lacks the NLS (nuclear localization sig-
nal) and is thus exclusively found in the cytosol. The functional
relevance of cytoplasmic PML was revealed in a seminal study
that showed its contribution for transforming growth factor beta
(TGFβ)-induced growth arrest and senescence. The necessity of
cytoplasmic PML for TGFβ-mediated signaling also relies on the
ability of PML to bind to the transcription factors Smad2/3 (Lin
et al., 2004). A further study showed that PML can also localize
to specific membrane structures that connect mitochondria with
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the endoplasmic reticulum. These membrane regions control
apoptosis through the regulation of calcium influx from the ER
to the mitochondria in a PML-dependent fashion. Accordingly,
PML−/− cells were protected from cell death induced by stim-
uli that rely on changes in Ca2+ signaling (Giorgi et al., 2010),
showing that PML also plays an important role outside from the
nucleus.
Various PTMs including phosphorylation, acetylation, ubiqui-
tination, ISGylation, and SUMOmodification can affect virtually
all protein functions. Most PTMs are added or removed by spe-
cialized enzymatic machineries which results in complex PTM
patterns that can be regulated in a signal- and cell type-specific
fashion (Jensen, 2006). The activities of PTM-mediating enzymes
such as protein kinases are themselves regulated by PTMs, thus
creating highly wired signaling networks. More than 1000 differ-
ent proteins serve as kinases or ubiquitin E3 ligases, providing
an impressing illustration for the complexity of these networks
(Manning et al., 2002; Deshaies and Joazeiro, 2009). The signal-
ing proteins do not work as single independent units but rather
function in dynamically interacting protein complexes. Most sig-
naling proteins of the numerous pathways known to be regulated
by PML occur in one or several stable or dynamic complexes. A
number of examples show that a given protein can, depending
on its molecular micro-environment and binding partners within
a given multi-protein signaling complex, serve different func-
tions (Vousden and Prives, 2009). The formation of multi-protein
assemblies, their stability, and enzymatic activity are tightly con-
trolled by PTMs, which act as reversible molecular switchboards.
Although not every single PTM might be involved in a spe-
cific function (Lienhard, 2008), the strong overrepresentation of
mutations in PTMmodifiers (such as kinases or ubiquitin E3 lig-
ases) in diseases such as cancer (Rikova et al., 2007; Puente et al.,
2011) argues for their relevance for cellular homeostasis.
The correct assembly of PML-NBs facilitates protein phos-
phorylation and the modification of lysines through attachment
of acetyl groups, ubiquitin chains, or ubiquitin-related pep-
tides such as SUMO or ISG15 (interferon-stimulated gene-15).
The analysis of a manually curated PML-NB interactome (Van
Damme et al., 2010) allowed the identification of many proteins
involved in SUMO modification, ubiquitination, phosphoryla-
tion, and acetylation. An updated list is displayed in Table 1.
Given the large repertoire of PTMs it will be interesting to see
whether PML-NBs are hotspots that are specialized for the above
mentioned PTMs or whether also other types of protein modi-
fications are enriched in these factories. As arginine methyltrans-
ferase 1 (PRMT1) is also found in PML-NBs (Boisvert et al., 2005)
it will be relevant to investigate whether also argininemethylation
is occurring in these subnuclear structures. The importance of
PML for PTMs is nicely exemplified for the tumor suppressor p53.
Expression of oncogenic Ras induces PML-mediated senescence
in a p53-dependent manner. Ras also triggers recruitment of p53
and the acetyltransferase CREB-binding protein (CBP) to PML-
NBs which results in the formation of a trimeric p53/PML/CBP
complex and p53 Lys382 acetylation (Pearson et al., 2000). Ras-
induced p53 acetylation and senescence are lost in PML−/−
fibroblasts, showing the relevance of PML for this critical process.
Further insight for the involved mechanism was provided by the
Table 1 | Post-translational modifiers in PML-NBs.
Kinases
Mtor
p38
HIPK1
HIPK2
CK2
CHEK2
CK1
Aurora kinase A
MNK2b
ATR
DAPK3
IKKε
AKT
Phosphatases
PP1A
PP2A
Ubiquitin conjugating proteins
RBCK1
FBX3
RNF63
TRIM69
TRIM27
SKP1
Cullin 1
Cullin 3
E6AP
CHFR
RNF4
TOPORS
KLHL20
Ubiquitin deconjugating proteins
USP45
USP7
Acetylation
CBP
p300
Tip60
Deacetylation
HDAC1
HDAC2
HDAC3
HDAC7
Sirt1
————————————————
Other enzymes
Pin1
PRMT1
SUMO conjugation
HDAC7
AOS1
UBA2
UBC9
RANBP2
RNF4
TOPORS
MEL-18
p14ARF
PIAS1
PIAS3
PIASy
PC2
PIAS2/x
SUMO deconjugation
SENP1-3
SENP5-7
A comprehensive list of PTM-regulating proteins and enzymes contained in
PML-NBs. Based on a published and manually curated network of the PML-
NB interactome (Van Damme et al., 2010) and an updated literature review
the PTM-regulating proteins are grouped according to the type of protein
modification.
finding that p53 Lys382 acetylation requires previous phospho-
rylation of p53 at Ser46 by the kinase homeodomain-interacting
protein kinase 2 (HIPK2) 2 (Hofmann et al., 2002). HIPK2-
mediated Ser46 phosphorylation depends on the presence of the
PML protein (Moller et al., 2003), explaining why also the asso-
ciated p53 acetylation is PML-dependent. Acetylation of p53 is
also impaired in cells expressing the oncogenic and dominant
negative PML-RARα fusion protein which is causative for acute
promyelocytic leukemia. This mechanism is dependent on his-
tone deacetylases (HDACs) and the deacetylated p53 protein
has a diminished activity, thus losing a substantial part of its
tumor-suppressing function (Insinga et al., 2004). But also casein
kinase 1 (CK1)-mediated phosphorylation of p53 at Thr18 is
regulated by PML. DNA damage causes the partial recruitment
of CK1 in PML-NBs where the kinase interacts with endoge-
nous p53 and PML, thus enhancing p53 Thr18 phosphorylation
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(Alsheich-Bartok et al., 2008). The importance of PML for p53
function is not only restricted to the wildtype protein (Bao-Lei
et al., 2006), but is also seen for gain-of-function p53 mutants
(Haupt et al., 2009).
PML also modulates the activity of protein phosphatases, as
seen for the protein phosphatases 1A and 2A (PP1A and PP2A).
PML recruits the AKT phosphatase PP2A and the phosphorylated
AKT (also known as PKB) protein into PML-NBs, thus ensur-
ing that the majority of AKT is present in the unphosphorylated,
inactive form (Trotman et al., 2006). The absence of PML leads
to an exaggerated AKT phosphorylation and concomitantly to
tumorigenesis in the prostate, a tissue that is sensitive to the levels
of phosphorylated AKT. At the molecular level, increased AKT
phosphorylation leads to impaired Foxo3a-mediated transcrip-
tion of proapoptotic and cell cycle inhibitory genes (Fei et al.,
2009).
But PML also serves as a regulator of acetylation events, as
revealed in a study that uncovered the contribution of PML
for enhanced fatty acid oxidation in metabolically hyperactive
breast cancer cells (Carracedo et al., 2012). This study showed
the contribution of PML for the regulation of the acetylation
status of the PPARγ coactivator 1A (PGC1A). PML expression
leads to reduced PGC1A acetylation and thus increases its activity
(Carracedo et al., 2012). As a result, PPAR signaling is enhanced
which in turn promotes fatty acid oxidation and helps to meet the
increased requirement for energy and biomass in highly prolifer-
ating cancer cells. Elevated fatty acid oxidation by the cooperation
between PML and PPAR transcription factors is also physiolog-
ically relevant for the maintenance of hematopoietic stem cells
(Ito et al., 2012).
A further PTM that is affected by PML-NBs is ubiquitination.
The accessory KLHL20 protein is contained in a multisubunit
ubiquitin E3 ligase complex and binds to death-associated pro-
tein kinase (DAPK), thus resulting in its ubiquitination which
in turn allows its proteasomal degradation. Stimulation of cells
with interferon leads to the enrichment of KLHL20 in PML-
NBs, thereby separating KLHL20 from DAPK which stops ubiq-
uitination and degradation of this kinase (Lee et al., 2010).
Conversely, PML-NBs can also regulate the activity of deubiqui-
tinating enzymes such as USP7. PML is required to inhibit USP7,
thus preventing the deubiquitination of the tumor suppressing
phosphatase PTEN. Disruption of PML-NB integrity by PML-
RARα leads to the ubiquitination of PTEN and to aberrant local-
ization of this phosphatase, thus facilitating cancer progression
(Song et al., 2008).
An open question relates to the specificity of the pathways
and PTMs regulated by PML-NBs. A previously published review
by Rosa Bernardi and Pier Paolo Pandolfi stated that “PML-
NBs have been implicated in the regulation of virtually every
biological function” (Bernardi and Pandolfi, 2007). It is cer-
tainly true that a large plethora of signaling pathways is regu-
lated by PML-NBs, but there seems to be an overrepresentation
of stress-related signaling events that range from (virus) infec-
tion to DNA damage or metabolic stress (Bischof et al., 2002;
Everett and Chelbi-Alix, 2007; Tavalai and Stamminger, 2009;
Carracedo et al., 2012). This would also be consistent with the
phenotype of PML-deficient mice that are largely normal under
convenient laboratory conditions, but show a variety of defects
when challenged with adverse agents (Bernardi and Pandolfi,
2007; Borden, 2008). Given the recent advances in mass spec-
trometry protocols, instrumentation, and data analysis it will be
exciting in the future to have a broader and more systematic
view on the PTM patterns that are controlled by this subnuclear
structure.
MODIFICATIONS OF PML
Structural PML-NB proteins such as PML and Sp100 and also
transiently contained residents undergo a variety of PTMs that
will be discussed here. The necessity for regulated PTMs which
in turn can regulate the functional properties of the modified
proteins comes from some general considerations: (1) PML-
NBs are dynamically regulated during the cell cycle by a fission
mechanism during S phase (Dellaire et al., 2006a). PML-NBs
disassembly during mitosis is paralleled by phosphorylation and
de-SUMOylation of PML proteins and their dissociation from
Sp100 (Everett et al., 1999; Dellaire et al., 2006b). In the G1 phase
the PML-NBs show an increased association with sites of active
transcription and enriched in hyperphosphorylated RNA Pol II
(Kiesslich et al., 2002). (2) PML-NBs can be seen as integration
and processing points for stress signals, as also discussed above.
The differentiation between the presence or absence of these
stress signals generally employs information processing steps that
transmit and display signals through changes in PTM patterns.
(3) It is tempting to speculate that the various PML-NBs con-
tained in a given cell may be functionally heterogeneous and
distinct, although experimental proof is missing. These (hypo-
thetical) functionally distinct PML-NBs could exert overlapping
but also specialized functions that could be defined by specific
PTMs patterns. Collectively, these points argue for the necessity of
basal and also signal-induced PTM patterns that allow the regula-
tion of PML-NB (dis)assembly and function. Here we will discuss
only modifications of PML and the PML-RARα fusion pro-
tein, but not of other important constituents of these subnuclear
structures.
PML PHOSPHORYLATION
Phosphorylations very often have their own functions, but as dis-
cussed in detail below, this modification can be coupled to ubiq-
uitination, SUMOylation, acetylation, and isomerization. Basal
phosphorylation of PML was shown in one of the early and sem-
inal papers in the PML field (Chang et al., 1995). Experimental
work from many groups in combination with data retrieval
from the public PhosphoSitePlus© database allows the descrip-
tion of >30 PML phosphorylation sites that are schematically
displayed in Figure 1 and also given in Table 2. Phosphorylation
sites are strongly enriched in the N-terminal region preceding
the RING domain. But they also cluster around the NLS and
the SUMO-interacting motif (SIM), which potentially allows
to control the subcellular localization of PML. The involved
kinases and physiological consequences of PML phosphoryla-
tion are only known for the minority of phosphorylated sites.
Modification of the N-terminus is mediated by several kinases
including HIPK2. DNA damage induces HIPK2 activity and
leads to direct PML phosphorylation at serines 8 and 38 as
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FIGURE 1 | Schematic display of the PML protein and its various domains. The distribution and clustering of phosphorylation sites is shown, the directly
phosphorylating kinases and their upstream regulators are indicated.
Table 2 | List of PML phosphorylation sites retrieved from published literature and the public PhosphoSitePlus© database.
Phosphorylation
site
Kinase PML domain Biological effect Conserved in mouse
S8 HIPK2 + apoptosis Yes
T28 ERK + apoptosis No
S36 ERK + apoptosis + PML-NB recruitment of IKKε Yes
S38 HIPK2, ERK + apoptosis Yes
S40 ERK + apoptosis No
S117 CHEK2 + apoptosis No
T184, S190 B2 box No/Yes
Y309, S399 DUF domain Yes/Yes
S403 ERK2 BMK1/ERK5 DUF domain + Pin1-mediated PML degradation Yes
S408 DUF domain Yes
T409 BMK1/ERK5 DUF domain − inhibition of PML-induced p21 induction Yes
S480, T482, S504 DUF domain Yes/No/Yes
S505 ERK2 DUF domain Yes
S512 CK2 DUF domain Yes
S518 CK2 DUF domain + tumor-suppression Yes
S527 ERK DUF domain No
S530 ERK DUF domain Yes
S535 DUF domain No
S560, S561, S562 CK2 Adjacent to SIM Yes/Yes/Yes
S565 CK2 + Pin1-mediated PML degradation Yes
S578, S580, S583,
S625, S804, T867,
S879
Yes/Yes/Yes
Yes/Yes/No
No
The list also indicates the involved kinases, evolutionary conservation to mouse and themodified domain. Enhanced and diminished biological functions are indicated
by + and −. The numbering of amino acids refers to full-length human PML-I.
revealed by in vitro kinase assays (Gresko et al., 2009). These
N-terminal phosphorylation sites further enhance DNA damage-
induced PML SUMOylation and are required for the ability of
PML to cooperate with HIPK2 for the induction of cell death.
Ser38 phosphorylation is also observed after overexpression of
IKKε, a kinase regulating innate immunity and DNA damage sig-
naling (Renner et al., 2010). In vitro kinase assays showed that
this IKKε-triggered phosphorylation is not direct, thus suggesting
the involvement of a downstream kinase. Immunofluorescence
experiments revealed that PML Ser38 phosphorylation is impor-
tant for its ability to transiently recruit IKKε to PML-NBs (Renner
et al., 2010). PML phosphorylation at Thr28, Ser36, Ser38, and
Ser40 is mediated by extracellular signal-regulated kinase (ERK)
after treatment with arsenic trioxide (As2O3). This phosphoryla-
tion is associated with increased SUMOylation of PML and ele-
vated As2O3-induced cell death (Hayakawa and Privalsky, 2004).
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ERK2 also phosphorylates PML at Ser403 and Ser505 which
allows docking of the prolyl-isomerase Pin1 which presumably
causes isomerization of PML (Lim et al., 2011). Docking of
Pin1 to PML then leads to destabilization of PML. Basal
PML phosphorylation at Ser403 and Ser505 is detectable in
unstimulated cells and can also be further induced by EGF
stimulation (Lim et al., 2011), implying that this mechanism
regulates PML levels under steady-state and inducible condi-
tions. The phosphorylation site at Ser403 can be also mediated
by BMK1/ERK5 (big MAP kinase). This kinase shows simi-
larity to the ERK family and modifies PML at Ser403 and
Thr409. Phosphorylation at these sites inhibits PML-dependent
activation of p21 by an unknown mechanism (Yang et al.,
2010).
Consistent with the function of PML-NBs in the DNA damage
response, several PML phosphorylating kinases with a role in the
DNAdamage response are known. The kinase ATR (ataxia telang-
iectasia and Rad3 related) phosphorylates PML at an unknown
site(s) which in turn results in the nucleolar translocation of
PML and the sequestration of MDM2 (Bernardi et al., 2004). As
MDM2 mediates constitutive ubiquitination of p53 and there-
fore limits its abundance, nucleolar sequestration of this E3
ligase leads to p53 stabilization and apoptosis. The kinase ataxia
telangiectasia mutated (ATM) can also regulate the number of
PML-NBs in response to DNA double-strand breaks, but this
effect is probably independent from direct PML phosphoryla-
tion and rather depends on ATM-mediated phosphorylation of
the KAP1 protein (Kepkay et al., 2011). DNA damage also acti-
vates checkpoint kinase 2 (CHEK2) which phosphorylates PML
at Ser117. Functional experiments showed that induction of PML
Ser117 phosphorylation is required for induction of cell death by
γ irradiation (Yang et al., 2002). PML phosphorylation at Ser518
is mediated by casein kinase-2 (CK2), a kinase that is frequently
found to be overexpressed in lung cancer. Consequently, a point
mutated version of PML that is refractory to CK2 phosphory-
lation displays increased tumor-suppressive functions (Scaglioni
et al., 2006). CK2-mediated PML phosphorylation also enhances
PML ubiquitination and degradation, thus also allowing control
of its abundance. In vitro kinase assays also revealed the ability of
CK2 to phosphorylate a patch of serines directly adjacent to the
C-terminal SIM (Stehmeier and Muller, 2009). These phospho-
rylations enhance the SUMO/SIM binding affinity and thus allow
regulation of this interaction which is also important for the for-
mation of PML-NBs (Lin et al., 2006; Shen et al., 2006; Sung et al.,
2011).
PML ACETYLATION
Acetylation was detected in cells that were treated with the HDAC
inhibitor trichostatin A (TsA). Similarly, PML acetylation was also
induced by overexpression of the lysine acetyl transferases p300
or GCN5 (Hayakawa et al., 2008). Mapping experiments allowed
the identification of Lys487 and Lys515 as the major acetyla-
tion sites in PML. A mass spectrometric analysis available from
the public PhosphoSitePlus© database confirmed acetylation at
Lys487 and allowed the identification of Lys490 and Lys497 as
additional modification sites (Hornbeck et al., 2012). PML acety-
lation is associated with increased PML SUMOylation, but the
molecular mechanisms mediating this coupling effect are not
understood. Cells expressing an acetylation-deficient mutant of
PML were refractory to TsA-induced cell death (Hayakawa et al.,
2008), but it is not clear whether this behavior can be attributed
to an impairment of SUMOylation or acetylation. Interestingly,
the acetylated Lys487 is contained in the NLS and thus acety-
lation of this residue can alter the localization of the modified
PML protein and regulate its localization to the nucleus or cyto-
plasm. Deacetylation of this residue by SIRT1 is critical for
nuclear localization of the circadian clock regulator Per2 (Miki
et al., 2012). Accordingly, PML/PER2-mediated enhancement
of BMAL1/CLOCK-mediated transcription is abolished upon
mutation of Lys487, revealing the functional relevance of this
acetylation site. As seminal studies showed that PML coimmuno-
precipitates a significant level of HDAC activity, the majority of
PML proteins will be in the non-acetylated state (Wu et al., 2001).
PML SUMOylation
Modification of proteins with SUMO is carried out in a multi-
step pathway. Similar to the conjugation of ubiquitin, the
SUMOylation machinery also includes E1, E2, and E3 enzymes
(Johnson et al., 1997). SUMO proteins are synthesized as precur-
sors that need to be proteolytically processed by sentrin/SUMO-
specific proteases (SENPs) to reveal a C-terminal diglycine motif.
The mature SUMO is then activated in an ATP-dependent man-
ner by the E1 enzyme (SAE2/Aos1) and catalyzes the formation
of a thioester bond between the C-terminal glycine of SUMO
and the catalytic cysteine residue of SAE2. SUMO is then trans-
ferred to the active site cysteine of the only known SUMO E2
conjugating enzyme Ubc9 (ubiquitin conjugating 9) (Johnson
and Blobel, 1997). Finally, Ubc9 transfers SUMO to the tar-
get protein. This reaction results in an isopeptide bond between
the C-terminal carboxy group of SUMO and the ε-amino group
of the acceptor lysine. This process is typically facilitated by
SUMO E3 ligases which are often SUMOylated themselves and/or
contain a SIM (Yeh, 2009; Gareau and Lima, 2010). PML is
among the first substrates that were found to be SUMO modi-
fied (Boddy et al., 1996; Sternsdorf et al., 1997). The early and
pioneering work on PML SUMOylation has generated tools and
knowledge that fueled the entire field of SUMO research. PML
is SUMOylated at three lysines by the SUMO family members
SUMO1, SUMO2, and SUMO3. PML can be SUMOylated at
Lys65 in the RING finger, Lys160 in the B1-box, and Lys490
in the NLS (Kamitani et al., 1998). These modifications occur
hierarchically as SUMOylation on Lys160 is a prerequisite for
SUMOylation on Lys65. High-resolutionmicroscopy enabled fas-
cinating insights into the architecture of PML-NBs and allowed
the detection of SUMO1 within aggregated spots in the PML-
Sp100 protein shell (Lang et al., 2010). The SUMO1-containing
patches also showed intrusions and extrusions from the PML
shell. The differential colocalization between PML and SUMO1
may also reflect different degrees of PML SUMOylation. In con-
trast SUMO2 and SUMO3 occurred in the interior of PML-
NBs (Lang et al., 2010). One important function of PML
SUMOylation is the formation of normal nuclear bodies (Ishov
et al., 1999; Zhong et al., 2000). Fluorescence recovery after pho-
tobleaching (FRAP) analysis showed that mutation of Lys160 and
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Lys490 drastically decreases the residence time of themutant PML
protein at the nuclear bodies (Weidtkamp-Peters et al., 2008). In
support for the structural relevance of SUMOylation, PML-NBs
are disrupted during mitosis as a result of de-SUMOylation
(Everett et al., 1999). But PML-NB structure also relies on the
ability of PML proteins to self-associate via the N-terminal RBCC
domain (Borden, 2008). This self-association would also explain
data showing that expression of a PML form mutated in all
three SUMOylated lysines still allows the formation of PML-NBs
(Lallemand-Breitenbach et al., 2001). The relevance of protein
SUMOylation for PML-NB architecture is also supported by the
analysis of SUMOylation-defective Ubc9−/− cells which show
PML-NB defects (Nacerddine et al., 2005). Stable assembly of
PML-NBs also relies on the presence of a SIM domain which
binds SUMO in a non-covalent manner. SIMs typically con-
sists of a hydrophobic core, which is often flanked by acidic
residues. SIM/SUMO interactions enhance or specify the inter-
action with other SUMOylated proteins. The relevance of the
PML SIM for PML-NB formation has been challenged by the
FRAP analysis of the PML isoform PML-VI which lacks a SIM.
The exchange rate of PML-VI at PML-NBs was only marginally
slower than exchange rates measured for SIM-containing PML
isoforms (Weidtkamp-Peters et al., 2008). However, these stud-
ies were performed in cells containing endogenous PML, raising
the possibility that the behavior of PML-VI could be influenced
by association with endogenous PML forms harboring a SIM.
The strength of SUMO/SIM interactions can be further regulated
by CK2-mediated phosphorylation of a patch of serines directly
adjacent to the C-terminal SIM (Stehmeier and Muller, 2009).
These interactions can also be controlled by acetylation of SUMO
which neutralizes basic charges and thus prevents binding to the
SIM of PML. Expression of an acetylation-mimicking form of
SUMO leads to a reduction in size and number of PML-NBs
and also prevents recruitment of Daxx (death-domain associated
protein) into these subnuclear structures (Ullmann et al., 2012).
Pharmacological evidence suggests that class I HDACs antagonize
SUMO acetylation, and it will be very interesting to identify the
physiologically relevant signals regulating the acetylation status
of SUMO in the future. Other functions of PML SUMOylation
depend on the conjugated SUMO isoform and on the length
of the poly-SUMO chain (Fu et al., 2005; Mukhopadhyay et al.,
2006). While the importance for branched SUMO2/3 chains for
subsequent ubiquitination of PML is discussed below, another
report highlights the special relevance of oligomerized SUMO3
for nuclear localization of PML (Fu et al., 2005).
The SUMOylation status of PML can be regulated by various
ways: these include enzymatic mechanisms executed by SUMO
ligases and proteolytic SENP enzymes, non-enzymatic mecha-
nisms such as the intracellular redox state (Bossis and Melchior,
2006) and probably also the relative availability and localiza-
tion of unconjugated SUMO1 and SUMO2/3 (Lang et al., 2010).
Basal SUMOylation is ensured by the direct binding of the PML
RING finger to the SUMO E2 enzyme Ubc9 (Duprez et al., 1999).
SUMOE3 ligases do not need a specialized catalytic center, as they
function by bridging the SUMO-loaded Ubc9 and the substrate
protein (Yeh, 2009; Gareau and Lima, 2010). This mechanism
of induced proximity is sufficient to enhance SUMOylation and
accordingly several enzymes have been proposed to function as
SUMO E3 ligases for PML. Conjugation of SUMO2 (but not of
SUMO1) is enhanced by RanBP2, suggesting that this E3 lig-
ase functions as a paralog-specific enzyme (Tatham et al., 2005).
Two further candidate enzymes have deacetylating functions:
one is HDAC7, which shows increased PML binding in TNF-
stimulated cells. The function as a SUMO E3 ligase was also
recapitulated in a cell-free system with purified components, thus
showing that this effect is direct (Gao et al., 2008). Another
deacetylase is the NAD-dependent enzyme SIRT1 which stimu-
lates PML SUMOylation in a deacetylase-independent manner
(Campagna et al., 2011). Also the PIAS1 protein was identi-
fied as a PML-interacting protein with the ability to enhance
PML SUMOylation, as revealed by in vivo and in vitro experi-
ments (Rabellino et al., 2012). The relative specificity of these
E3 enzymes is probably limited, as a given SUMO E3 ligase can
typically enhance the SUMOylation status of several different
substrate proteins. It will therefore be interesting to investigate
SUMOylation of the endogenous PML protein in the absence
of one or several of these discussed E3 ligases to reveal their
relative contribution in different signaling pathways. Enzymatic
de-SUMOylation of PML is mediated by several SENPs. SENP-
1 decreases PML SUMOylation after treatment of cells with
IL-6 (Ohbayashi et al., 2008). Transient transfection experiments
showed that SENP-5 can remove SUMO2 or SUMO3 from Lys160
or Lys490, but it failed to remove SUMO1 from these two posi-
tions. On the other hand, SENP-5 expression resulted in the
deconjugation of all three SUMO isoforms from Lys65 (Gong
and Yeh, 2006). Poly-SUMO-modified PML is also a substrate
of SENP6 which shows preference for SUMO polymers and
is specific for SUMO2/3-modified substrates. Si-RNA-mediated
depletion of SENP-6 results in an elevated number and size of
PML-NBs and allows detection of increased PML SUMOylation
(Tatham et al., 2005; Hattersley et al., 2011).
PML ISGylation AND UBIQUITINATION
The PML-RARα fusion protein can be modified by the ubiquitin-
related protein ISG15. Also conjugation of ISG15 occurs in an
E1/E2/E3-dependent manner and ISGylation of the PML domain
in PML-RARα has been observed after overexpression of the E1-
like ubiquitin-activating enzyme for ISG15 (Shah et al., 2008).
It will be interesting to identify the modified site and to mea-
sure the physiological regulation of this PTM. The conjugation
of ubiquitin chains to proteins has different consequences. While
attachment of Lys48-linked chains leads to subsequent proteaso-
mal destruction of the modified protein, the attachment of non-
Lys48-branched ubiquitin chains has regulatory consequences
(Varshavsky, 2012). Similar to the SUMO system, also ubiquitina-
tion is an ATP-dependent process that proceeds by an E1, E2, and
E3 cascade. Ubiquitin E3 ligases fall into several groups includ-
ing the largest group of RING finger and RING finger-related E3s
(Budhidarmo et al., 2012). Given the central relevance of PML
as a highly connected hub that integrates and regulates a mul-
titude of different signaling pathways it is not surprising to see
that PML ubiquitination employs many different ubiquitin E3
ligases. Physiologically relevant ubiquitin-dependent degradation
of PML occurs to control its half-life in unstimulated cells and
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also after stimuli such as hypoxia that lead to its degradation
(Lallemand-Breitenbach et al., 2008; Tatham et al., 2008; Yuan
et al., 2011). PML degradation and disruption of PML-NBs can
be also exerted by the herpes simplex virus type 1 (HSV-1)
immediate-early protein ICP0 (Cuchet-Lourenco et al., 2012).
ICP0 directly interacts with PML-I and degradation of its interac-
tion partner depends on an intact RING finger motif in this viral
ubiquitin E3 ligase (Maul and Everett, 1994; Boutell et al., 2002;
Gu and Roizman, 2003). Also hypoxia-mediated degradation of
PML proceeds by a SUMO-independent pathway. Hypoxic con-
ditions reduce the half-life of the PML protein and also lead to
its increased ubiquitination (Yuan et al., 2011). Hypoxia leads to
CDK1/2-mediated phosphorylation of PML at Ser518 by mecha-
nisms that are poorly understood. This phosphorylation in turn
creates a docking site for Pin1, which presumably causes con-
formational changes. The importance of Pin1 is underscored by
the finding that Pin1 depletion also abrogates hypoxia-induced
PML destruction. Prolyl-isomerization allows for subsequent
recruitment of components of a multi-subunit ubiquitin E3 lig-
ase complex (Yuan et al., 2011). The recruited components are
Cullin-3 and the substrate adaptor KLHL20 which are required
for hypoxia-induced ubiquitination of PML but also for steady
state ubiquitination under normoxic conditions. The analysis of
human prostate cancer showed that overexpression of KLHL20
and Pin1 correlates with down-regulation of PML, suggesting
that this proteolytic pathway is also of pathophysiological rele-
vance (Yuan et al., 2011). Another PML-destructing mammalian
E3 ligase is E6AP (HPV E6-associated protein). Its overexpres-
sion causes the ubiquitination and proteasomal degradation of
PML, while cells lacking this E3 ligase shows elevated PML lev-
els. In vitro experiments with purified proteins showed that E6AP
triggers the ubiquitination of PML (Louria-Hayon et al., 2009),
which proofs that E6AP fulfills all criteria for a bonafide PML E3
ligase. The pathophysiological relevance of the E6AP-PML axis
for development of B-cell lymphoma has been provided in mouse
models where E6AP heterozygous mice were crossed with Eμ-
myc transgenic mice which are a widely used model to study
Burkitt lymphoma. E6AP heterozygosity resulted in a significantly
delayed onset of Myc-induced lymphomagenesis. Lymphoid cells
from Eμ-myc/E6AP+/− mice showed increased levels of PML
and concomitant elevated PML-mediated senescence (Wolyniec
et al., 2012). The analysis of patient material showed increased
E6AP expression in 60% of human Burkitt lymphomas. As down-
regulation of E6AP in B-lymphoma cells restores expression of the
tumor suppressor PML (Wolyniec et al., 2012), this ubiquitin E3
ligase would be an attractive drug target for the treatment of non-
Hodgkin lymphomas. But this statement is also true for the other
E3 ligases acting on PML, as it could restore expression of the
tumor suppressor PML which is lost or reduced in many differ-
ent human tumors (Bernardi and Pandolfi, 2007; Salomoni et al.,
2012).
MODIFICATIONS OF PML-RARα
PML-RARα PHOSPHORYLATION
While our knowledge on PML phosphorylation is steadily grow-
ing, less is known about this modification in the oncogenic
PML-RARα fusion protein. Fusion of the Pml gene to the retinoic
acid (RA) receptor α (Rarα) gene by the t(15,17) chromosomal
translocation generates a fusion protein that preserves the N-
terminal part of PML including its phosphorylation sites (De
The et al., 1991; Kakizuka et al., 1991). Changes in the overall
structure and localization of PML-RARα will presumably gener-
ate phosphorylation patterns that are distinct from the wildtype
PML. But also differences in the kinetics can occur, as exempli-
fied for DNA damage induced phosphorylation of Ser38 which
is readily induced for PML and only occurs in a delayed fash-
ion for PML-RARα (Gresko et al., 2009). RA is frequently used to
treat PML and this agent also triggers growth arrest of leukemia-
initiating cells (LICs). The cAMP-dependent phosphorylation of
PML-RARα Ser873 is critical for PML-RARα degradation and
subsequent clearance of LICs (Nasr et al., 2008). RA- or cAMP-
initiated phosphorylation of the RARα moiety of the PML-RARα
protein occurs at RARα Ser369. This phosphorylation can be
exerted by MSK1 and allows cyclin-dependent kinase 7 (CDK7)
to phosphorylate RARα at Ser77 (Gaillard et al., 2006; Bruck
et al., 2009). Mutation of the Ser369 phosphorylation site in PML-
RARα yields a protein with decreased sensitivity to RA-triggered
degradation which results in resistance to RA (Nasr et al., 2008).
These data show the relevance of PML-RARα phosphorylation
for clinically relevant degradation of this oncogenic fusion pro-
tein, and emphasize the necessity to learnmore about PML-RARα
phosphorylation in the future.
PML-RARα ACETYLATION
Presently only indirect evidence suggests a functional role of
PML-RARα acetylation for disease progression, as revealed by
pharmacological evidence in a transgenic mouse model. PML-
RARα expressing mice develop leukemia which is responsive
to RA treatment. This mouse model recapitulates the function
of PML-RARα as a transcriptional repressor and the repressor
activity is lost upon treatment of cells with RA in combina-
tion with TsA (He et al., 1998). It will be interesting to study
whether the TsA activity is attributable to increase acetylation
of the PML-RARα protein or other factors. Acetylation occurs
for lysines, residues that can be also modified by ubiquitination
and SUMOylation. It is therefore possible that PML acetylation
has also an impact on the other two modifications which are
frequently found in competition for unmodified side chains of
lysines (Li et al., 2012).
PML-RARα SUMOylation
The PML-RARα fusion protein still contains two of the three
PML SUMOylation sites at Lys65 and Lys160. Data obtained
in cell models and transgenic animals show the necessity
of the Lys160 SUMOylation site in the PML moiety of the
fusion protein for the development of acute PML (Zhu et al.,
2005). Lys160 SUMOylation is important for binding to the
transcriptional repressor Daxx, raising the possibility that Daxx-
mediated gene repression is important for leukemic trans-
formation. SUMOylation of PML-RARα is also required for
arsenic trioxide-induced degradation of PML-RARα. Several
mechanisms lead to arsenic-triggered SUMOylation of PML-
RARα, which is the prerequisite for its ubiquitin-mediated
degradation as discussed below. Arsenic causes oxidative stress
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(Kawata et al., 2007), which facilitates the formation of disul-
fide bonds between PML proteins, thus resulting in PML mul-
timerization and targeting to nuclear bodies (Jeanne et al.,
2010). In addition, arsenic directly binds to PML cysteines,
which allows enhanced binding of Ubc9 and elevated PML
SUMOylation (Jeanne et al., 2010; Zhang et al., 2010). Arsenic
causes the modification of PML/ RARα at Lys65 and Lys160 by
mixed poly-SUMOylation chains containing all three SUMO iso-
forms (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008;
Weisshaar et al., 2008). The SUMOylation state of PML-RARα is
also regulated by E3 ligases such as PIAS1 (Rabellino et al., 2012),
but is not clear whether E3 ligases or accessory proteins contribute
to the arsenic-induced SUMOylation.
PML-RARα UBIQUITINATION
Of special pathophysiological interest is the ubiquitin-dependent
degradation of PML-RARα by two clinically active drugs,
arsenic, and RA. A SUMO-ubiquitin-cascade has been identi-
fied by several groups as the molecular mechanism leading to
the arsenic-mediated degradation of PML-RARα (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008; Weisshaar et al.,
2008). The initial arsenic-induced Lys160 poly-SUMOylation cre-
ates docking sites for the ubiquitin ligase RNF4 (RING finger
protein 4) which harbors 4 SIMs and thus can be anchored
on these mixed chains. RNF4 in turn can decorate PML by
Lys48-branched ubiquitin at Lys401 and probably further sites
and thus cause its proteasomal elimination. RNF4 cannot dis-
criminate between SUMO paralogs, raising the possibility that
also mixed poly-SUMO chains function in the PML degrada-
tion pathway (Tatham et al., 2008). This mechanism does not
only occur for PML-RARα but is principally similar in PML
which is also degraded by arsenic. As PML SUMOylation is
the primary event that is followed by polyubiquitination, the
initial SUMO modification is the decisive and critical step.
Accordingly, mutation of the SUMOylation site at Lys160 ren-
ders the mutated PML protein resistant to arsenic-induced
degradation (Lallemand-Breitenbach et al., 2008). While these
elegant studies revealed a detailed mechanism for arsenic-
triggered PML-RARα degradation, the mechanisms mediating
RA-induced PML-RARα elimination are less clear. This prote-
olytic pathway is dependent on transcriptional activation and
requires DNA binding and the ligand-dependent transactivat-
ing domain (Zhu et al., 1999). This RA-induced transcrip-
tional program results in the proteasome-mediated destruction
of PML-RARα, but the involved molecules and ubiquitina-
tion events remain unclear. Two further family members of
FIGURE 2 | Selected examples for the occurrence of hierarchical and combinatorial PML PTMs. Phosphorylation (p), acetylation (Ac), mono- and
poly-SUMOylation (S and S-S), and polyubiquitination (Ubi-Ubi) are shown, the involved enzymes are displayed.
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RING ubiquitin E3 ligases have been identified as mediators of
PML-RARα degradation: SIAH1 and SIAH2 (seven in absentia
homolog 1/2). Overexpression of either SIAH1 or SIAH2 leads to
the ubiquitin/proteasome-dependent degradation of PML-RARα
(Pietschmann et al., 2012), but it is currently not known whether
this process controls basal or signal-induced degradation of
PML-RARα.
OUTLOOK
Apparently, many of the PML modifications occur in hierarchi-
cal and timely organized fashion, as schematically summarized
in Figure 2. Phosphorylation or acetylation events constitute typ-
ical starting points of many PTM cascades, while degradative
ubiquitination is a characteristic irreversible end point. How
can it be that PML is targeted by so many different modifying
enzymes? Given its involvement in a plethora of biological func-
tions it is certainly one of the central signaling hubs that needs
to be controlled and fine-tuned by many different signaling path-
ways. The rapid development of mass spectrometric methodology
and instrumentation will allow the identification of more and
probably also novel PTMs in PML-NBs. It will also be relevant
to clearly distinguish between PTM patterns that occur under
unstimulated basal steady-state conditions or in response to spe-
cific signals in a more systematic fashion. Mass spectrometry can
also clarify whether some PML modifications are restricted to
specific cells or tissues which would open further avenues for
research. Future work will also identify more of the transiently
recruited PML-NB modifiers that serve to regulate the modifica-
tion status of PML. It will be interesting in future experiments
to quantify the occurrence and regulation of PML modifica-
tion using stable isotope labeling by amino acids in cell culture
(SILAC) experiments. Some modifications such as phosphory-
lation or acetylation can be detected with modification-specific
antibodies, thus enabling the determination of individual modi-
fications for endogenous PML proteins. These antibodies would
also be instrumental to analyze the possible occurrence of spe-
cialized subgroups of PML-NBs. The functional role of individual
modifications can be revealed by the analysis of knockinmice that
express PML variants that are mutated in individual modification
sites.
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